Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

Ruriko Tanaka, Matthew S. Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver G. Ottmann, Taira Maekawa

Blood (2010) 116 (12): 2089–2095.

https://doi.org/10.1182/blood-2009-03-211466

Published: 2010

Includes: Supplemental data

Journal Articles

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Rina Nagao, Tatsutoshi Nakahata, M.D., Ph.D., Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2166.

https://doi.org/10.1182/blood.V114.22.2166.2166

Published: 2009

Journal Articles

Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.

Rina Nagao, Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Hisayuki Yao, MD, Miki Takeuchi, MD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Hideyo Hirai, MD, PhD, Jeffrey W Strovel, Janak Padia, Wieslaw M Cholody, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2184.

https://doi.org/10.1182/blood.V114.22.2184.2184

Published: 2009

Journal Articles

Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.

Asumi Yokota, MMSc, Shinya Kimura, MD, PhD, Ruriko Tanaka, MMSc, Miki Takeuchi, MD, Hisayuki Yao, MD, Kazuki Sakai, MD, Rina Nagao, Eishi Ashihara, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 4245.

https://doi.org/10.1182/blood.V114.22.4245.4245

Published: 2009

Journal Articles

A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.

Rina Nagao, Shinya Kimura, MD, PhD, Eishi Ashihara, MD, PhD, Miki Takeuchi, MD, Ruriko Tanaka, MMSc, Asumi Yokota, MMSc, Hisayuki Yao, MD, Jeffrey W Strovel, Wieslaw M Cholody, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1081.

https://doi.org/10.1182/blood.V112.11.1081.1081

Published: 2008

Journal Articles

Roles of Osteoclasts in Leukemic Cells

Asumi Yokota, MMSc, Shinya Kimura, MD, PhD, Ruriko Tanaka, MMSc, Rina Nagao, Kazuki Sakai, MD, Hisayuki Yao, MD, Miki Takeuchi, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Eishi Ashihara, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3184.

https://doi.org/10.1182/blood.V112.11.3184.3184

Published: 2008

Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3185.

https://doi.org/10.1182/blood.V112.11.3185.3185

Published: 2008

Journal Articles

Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus-Host Disease.

Eishi Ashihara, MD, PhD, Kazuho Shimura, MD, Chihiro Shimazaki, MD, PhD, Shinsaku Matsunaga, MD, Ruriko Tanaka, Asumi Yokota, Yoshihide Murotani, MD, Miki Takeuchi, MD, Eri Kawata, MD, Yuri Kamitsuji, MD, Junya Kuroda, MD, PhD, Masafumi Taniwaki, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD

Blood (2007) 110 (11): 1078.

https://doi.org/10.1182/blood.V110.11.1078.1078

Published: 2007

Journal Articles

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa

Blood (2007) 110 (11): 2931.

https://doi.org/10.1182/blood.V110.11.2931.2931

Published: 2007

NARROW

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.

Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.

A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.

Roles of Osteoclasts in Leukemic Cells

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus-Host Disease.

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only